Latest Content

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact.

Dr. Joseph Mikhael, chief medical officer of the International Myeloma Foundation, provided updates from the front lines of treatment advancement.

Dr. Marleen Meyers discusses improving survival rates, the evolving needs of younger cancer survivors and how caregivers can sustain long-term support.

New FDA approvals target mutations in lung cancer, improving outcomes, while clinicians refine strategies to manage immunotherapy-related side effects.

Though I don’t understand why I’m suffering, I try to hold onto my faith and believe that God is somehow still working in me.

A UCLA study found CAR-NKT cells eliminated endometrial tumors in models and showed stronger activity than existing immunotherapies, supporting further clinical development.

Survey shows 92% of eligible adults support coverage for colorectal cancer blood tests to improve screening access and adherence.

At CURE, we strive to provide insight, education and inspiration for patients, survivors and caregivers at every stage of the cancer journey.

Survivor Casey Liening discusses her metastatic breast cancer journey, reaching NED, and why a stage 4 diagnosis is a beginning, not a death sentence.

Dr. Jennifer Amengual explains how epigenetic therapies treat lymphomas by changing gene expression rather than killing dividing cells like chemotherapy.

Personalized treatment, exercise and supportive care improve outcomes for patients with metastatic hormone-sensitive prostate cancer.